UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/500,093	11/17/2004	Abedawn Khalaf	17856-002US1	7660

26161 7590 06/13/2007
FISH & RICHARDSON PC
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
HA, JULIE	
ART UNIT	PAPER NUMBER
1654	

MAIL DATE	DELIVERY MODE
06/13/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/500,093	KHALAF ET AL.	
	Examiner	Art Unit	
	Julie Ha	1654	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☐ Responsive to communication(s) filed on _____.

2a)☐ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) 50-94 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☐ Claim(s) _____ is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☒ Claim(s) 50-94 are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

Preliminary amendment filed on June 24, 2004 is acknowledged. Claims 1-49 were cancelled and new claims 50-94 are added. Claims 50-94 are pending in this application.

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claim(s) 75 and 83-85, drawn to a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-H-pyrrol-3-yl]-4-[(3,3-dimethylbutanoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide and the first method, method of treatment of a disease that relies upon DNA replication with a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-H-pyrrol-3-yl]-4-[(3,3-dimethylbutanoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide..

Group 2, claim(s) 75, drawn to a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 3, claim(s) 75 and 76-77, drawn to a compound N-[3-(-(Dimethylamino)propyl]2-2({[4-({[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 4, claim(s) 75, drawn to a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-({[4-(formylamino)-1-isopropyl-1H-pyrrol-2-yl]carbonyl}-amino)-1-isopropyl-1H-pyrrole-2-carboxamide.

Group 5, claim(s) 75, drawn to a compound N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopentyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(formyl-amino)-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 6, claim(s) 75, drawn to a compound N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-(formyl-amino)-1-isopropyl-1H-pyrrole-2-carboxamide.

Group 7, claim(s) 75 and 76, drawn to a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]2-({[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 8, claim(s) 75, drawn to a compound 4-({[4-(Formylamino)-1-methyl-1-H-pyrrol-2-yl]carbonyl}amino)1-isopropyl-N-[1-methyl-5-({3-(4-morpholinyl)propyl]amino}carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-2-carboxamide.

Group 9, claim(s) 75, drawn to a compound 4-(Formylamino)-N-[1-isopropyl-5-([[1-methyl-5-([[3-(1-pyrrolidinyl)-propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl- 1H-pyrrole-2-carboxamide.

Group 10, claim(s) 75 and 76, drawn to a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1- H-pyrrole-2-carboxamide.

Group 11, claim(s) 75, drawn to a compound 2-(Acetylamino)-N-[5-([[5-([[3-(dimethylamino)propyl]amino]-carbonyl)-1-m- ethyl-1H-pyrrol-3-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 12, claim(s) 75, drawn to a compound 2-(Acetylamino)-N-[5-([[4-([[3-(dimethylamino)propyl]amino]-carbonyl)-5-i- sopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 13, claim(s) 75, drawn to a compound 2-(Acetylamino)-N-(5-[[(3-[[3-(dimethylamino)propyl]amino]-3-oxo-propyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 14, claim(s) 75, drawn to a compound N^1,N^3-Bis(2-[[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)- -5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-amino]-2-oxoethyl)isophthalamide.

Group 15, claim(s) 75, drawn to a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-(acetylamino)-1-methyl-1-H-pyrrole-2-carboxamide.

Group 16, claim(s) 75, drawn to a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(acetyl-amino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 17, claim(s) 75, drawn to a compound N^2,N^5-Bis[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 18, claim(s) 75 and 76, drawn to a compound N^2,N^5-Bis[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]-amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 19, claim(s) 75, drawn to a compound N^2,N^5-Bis[5-([[5-([[3-(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 20, claim(s) 75, drawn to a compound N^2,N^5-Bis[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)-propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 21, claim(s) 75, drawn to a compound 2-([[4-([[4-(Acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]-amino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino)-N-[3-(dimethylamino)-propyl]-5-isoprop-yl-1,3-thiazole-4-carboxamide.

Group 22, claim(s) 75, drawn to a compound 4-(Acetylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl) propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide.

Group 23, claim(s) 75, drawn to a compound N-[1-Isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)-propyl]amino-]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 24, claim(s) 75, drawn to a compound N-[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-([[5-(formylamino)-2-methyl-3-thienyl]carbonyl]amino)-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 25, claim(s) 75, drawn to a compound N-[5-([[5-([[3-(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-2-[(3-methoxybenzoyl)amino]-1,3-thiazole-4-carboxamide.

Group 26, claim(s) 75 and 76, drawn to a compound N-[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-[[(5-[[(9,10-dioxo-

9,10-dihydro-2-anthracenyl)carbonyl]-amino]-2-methyl-- 3-thienyl)carbonyl]amino]-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 27, claim(s) 75, drawn to a compound N-[1-(Cyclopropylmethyl)-5-([[5-([[3-(dimethylamino)propyl]-amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 28, claim(s) 75, drawn to a compound 1-Cyclopentyl-N-[5-([[3-(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H- -pyrrol-3-yl]-4-([[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]-carbonyl]-amino)-1H-pyrrole-2-carboxamide.

Group 29, claim(s) 75 and 76, drawn to a compound N^2,N^7-Bis[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide.

Group 30, claim(s) 75, drawn to a compound 4-(Formylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide.

Group 31, claim(s) 75, drawn to a compound 4-(Acetylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1-H-pyrrole-2-carboxamide.

Group 32, claim(s) 75, drawn to a compound 4-(Formylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1-H-pyrrole-2-carboxamide.

Group 33, claim(s) 75, drawn to a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 34, claim(s) 75, drawn to a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-[[(4-methoxyphenyl)acetyl]amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 35, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 36, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[3-(-(Dimethylamino)propyl]2-2({[4-({[4-

(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 37, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-({[4-(formylamino)-1-isopropyl-1H-pyrrol-2-yl]carbonyl}-amino)-1-isopropyl-1H-pyrrole-2-carboxamide.

Group 38, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopentyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(formyl-amino)-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 39, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-(formyl-amino)-1-isopropyl-1H-pyrrole-2-carboxamide.

Group 40, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]2-({[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 41, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound 4-({[4-(Formylamino)-1-methyl-1-H-pyrrol-2-yl]carbonyl}amino)1-isopropyl-N-[1-methyl-5-({3-(4-morpholinyl)propyl]amino}carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-2-carboxamide.

Group 42, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound 4-(Formylamino)-N-[1-isopropyl-5-([[1-methyl-5-([[3-(1-pyrrolidinyl)-propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl- 1H-pyrrole-2-carboxamide.

Group 43, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1- H-pyrrole-2-carboxamide.

Group 44, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound 2-(Acetylamino)-N-[5-([[5-([[3-(dimethylamino)propyl]amino]-carbonyl)-1-m- ethyl-1H-pyrrol-3-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 45, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound 2-(Acetylamino)-N-[5-([[4-([[3-(dimethylamino)propyl]amino]-carbonyl)-5-i- sopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 46, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound 2-(Acetylamino)-N-(5-[[(3-[[3-(dimethylamino)propyl]amino]-3-oxo-propyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 47, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N^1,N^3-Bis(2-[[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)- -5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-amino]-2-oxoethyl)isophthalamide.

Group 48, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-(acetylamino)-1-methyl-1-H-pyrrole-2-carboxamide.

Group 49, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(acetyl-amino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 50, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N^2,N^5-Bis[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 51, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N^2,N^5-Bis[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]-amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 52, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N^2,N^5-Bis[5-([[5-([[3-(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 53, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N^2,N^5-Bis[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)-propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 54, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound 2-([[4-([[4-(Acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]-amino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino)-N-[3-(dimethylamino)-propyl]-5-isoprop-yl-1,3-thiazole-4-carboxamide.

Group 55, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound 4-(Acetylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl) propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide.

Group 56, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[1-Isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)-propyl]amino-]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 57, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-([[5-(formylamino)-2-methyl-3-thienyl]carbonyl]amino)-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 58, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-([[5-([[3-(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-2-[(3-methoxybenzoyl)amino]-1,3-thiazole-4-carboxamide.

Group 59, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-[[(5-[[(9,10-dioxo-9,10-dihydro-2-anthracenyl)carbonyl]-amino]-2-methyl-- 3-thienyl)carbonyl]amino]-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 60, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[1-(Cyclopropylmethyl)-5-([[5-([[3-(dimethylamino)propyl]-amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 61, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound 1-Cyclopentyl-N-[5-([[3-(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H- -pyrrol-3-yl]-4-([[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]-carbonyl]-amino)-1H-pyrrole-2-carboxamide.

Group 62, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N^2,N^7-Bis[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide.

Group 63, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound 4-(Formylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide.

Group 64, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound 4-(Acetylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1-H-pyrrole-2-carboxamide.

Group 65, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound 4-(Formylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1-H-pyrrole-2-carboxamide.

Group 66, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 67, claim(s) 83-85, drawn to a method of treatment of a disease that relies upon DNA replication with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-[[(4-methoxyphenyl)acetyl]amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 68, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-H-pyrrol-3-yl]-4-[(3,3-dimethylbutanoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 69, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 70, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[3-(-(Dimethylamino)propyl]2-2({[4-({[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 71, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-({[3-

(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-({[4-(formylamino)-1-isopropyl-1H-pyrrol-2-yl]carbonyl}-amino)-1-isopropyl-1H-pyrrole-2-carboxamide.

Group 72, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopentyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(formyl-amino)-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 73, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-(formyl-amino)-1-isopropyl-1H-pyrrole-2-carboxamide.

Group 74, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]2-({[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 75, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound 4-({[4-(Formylamino)-1-methyl-1-H-pyrrol-2-yl]carbonyl}amino)1-isopropyl-N-[1-methyl-5-({3-(4-morpholinyl)propyl]amino}carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-2-carboxamide.

Group 76, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound 4-(Formylamino)-N-[1-isopropyl-5-([[1-methyl-5-([[3-(1-pyrrolidinyl)-propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl- 1H-pyrrole-2-carboxamide.

Group 77, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1- H-pyrrole-2-carboxamide.

Group 78, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound 2-(Acetylamino)-N-[5-([[5-([[3-(dimethylamino)propyl]amino]-carbonyl)-1-m- ethyl-1H-pyrrol-3-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 79, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound 2-(Acetylamino)-N-[5-([[4-([[3-(dimethylamino)propyl]amino]-carbonyl)-5-i- sopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 80, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound 2-(Acetylamino)-N-(5-[[(3-[[3-(dimethylamino)propyl]amino]-3-oxo-propyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 81, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N^1,N^3-Bis(2-[[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)- -5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-amino]-2-oxoethyl)isophthalamide.

Group 82, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-(acetylamino)-1-methyl-1-H-pyrrole-2-carboxamide.

Group 83, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(acetyl-amino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 84, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N^2,N^5-Bis[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 85, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N^2,N^5-Bis[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]-amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 86, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N^2,N^5-Bis[5-([[5-([[3-(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 87, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N^2,N^5-Bis[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)-propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 88, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound 2-([[4-([[4-(Acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]-amino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino)-N-[3-(dimethylamino)-propyl]-5-isoprop-yl-1,3-thiazole-4-carboxamide.

Group 89, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound 4-(Acetylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl) propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide.

Group 90, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[1-Isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)-propyl]amino-]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 91, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-([[5-(formylamino)-2-methyl-3-thienyl]carbonyl]amino)-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 92, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-([[5-([[3-(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-2-[(3-methoxybenzoyl)amino]-1,3-thiazole-4-carboxamide.

Group 93, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-[[(5-[[(9,10-dioxo-9,10-dihydro-2-anthracenyl)carbonyl]-amino]-2-methyl-- 3-thienyl)carbonyl]amino]-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 94, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[1-(Cyclopropylmethyl)-5-([[5-([[3-(dimethylamino)propyl]-amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 95, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound 1-Cyclopentyl-N-[5-([[3-(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H- -pyrrol-3-yl]-4-([[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]-carbonyl]-amino)-1H-pyrrole-2-carboxamide.

Group 96, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N^2,N^7-Bis[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide.

Group 97, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound 4-(Formylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide.

Group 98, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound 4-(Acetylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1-H-pyrrole-2-carboxamide.

Group 99, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound 4-(Formylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1-H-pyrrole-2-carboxamide.

Group 100, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 101, claim(s) 90, drawn to a method of inhibiting DNA replication comprising contacting the DNA with an inhibitory amount of a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-[[(4-methoxyphenyl)acetyl]amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 102, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-H-pyrrol-3-yl]-4-[(3,3-dimethylbutanoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 103, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 104, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[3-(-(Dimethylamino)propyl]2-2({[4-({[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 105, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-({[4-(formylamino)-1-isopropyl-1H-pyrrol-2-yl]carbonyl}-amino)-1-isopropyl-1H-pyrrole-2-carboxamide.

Group 106, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopentyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(formyl-amino)-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 107, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-(formyl-amino)-1-isopropyl-1H-pyrrole-2-carboxamide.

Group 108, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]2-({[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 109, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound 4-({[4-(Formylamino)-1-methyl-1-H-pyrrol-2-yl]carbonyl}amino)1-isopropyl-N-[1-methyl-5-({3-(4-morpholinyl)propyl]amino}carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-2-carboxamide.

Group 110, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound 4-(Formylamino)-N-[1-isopropyl-5-([[1-methyl-5-([[3-(1-pyrrolidinyl)-propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl- 1H-pyrrole-2-carboxamide.

Group 111, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1- H-pyrrole-2-carboxamide.

Group 112, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a

compound 2-(Acetylamino)-N-[5-([[5-([[3-(dimethylamino)propyl]amino]-carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 113, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound 2-(Acetylamino)-N-[5-([[4-([[3-(dimethylamino)propyl]amino]-carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 114, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound 2-(Acetylamino)-N-(5-[[(3-[[3-(dimethylamino)propyl]amino]-3-oxo-propyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 115, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N^1,N^3-Bis(2-[[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)- -5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-amino]-2-oxoethyl)isophthalamide.

Group 116, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-(acetylamino)-1-methyl-1-H-pyrrole-2-carboxamide.

Group 117, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(acetyl-amino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 118, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N^2,N^5-Bis[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 119, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N^2,N^5-Bis[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]-amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 120, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N^2,N^5-Bis[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)-propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 121, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N^2,N^5-Bis[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)-propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 122, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound 2-([[4-([[4-(Acetylamino)-1-methyl-1H-imidazol-2-yl]carbonyl]-amino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino)-N-[3-(dimethylamino)-propyl]-5-isoprop-yl-1,3-thiazole-4-carboxamide.

Group 123, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound 4-(Acetylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl) propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide.

Group 124, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[1-Isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)-propyl]amino-]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 125, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-([[5-(formylamino)-2-methyl-3-thienyl]carbonyl]amino)-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 126, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-([[5-([[3-(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-2-[(3-methoxybenzoyl)amino]-1,3-thiazole-4-carboxamide.

Group 127, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a

compound N-[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-[[(5-[[(9,10-dioxo-9,10-dihydro-2-anthracenyl)carbonyl]-amino]-2-methyl-- 3-thienyl)carbonyl]amino]-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 128, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[1-(Cyclopropylmethyl)-5-([[5-([[3-(dimethylamino)propyl]-amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 129, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound 1-Cyclopentyl-N-[5-([[3-(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H--pyrrol-3-yl]-4-([[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]-carbonyl]-amino)-1H-pyrrole-2-carboxamide.

Group 130, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N^2,N^7-Bis[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide.

Group 131, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound 4-(Formylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide.

Group 132, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound 4-(Acetylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1-H-pyrrole-2-carboxamide.

Group 133, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound 4-(Formylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1-H-pyrrole-2-carboxamide.

Group 134, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-

yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 135, claim(s) 91, drawn to a method of stabilizing a DNA duplex formed between first and second single strands of DNA, comprising contacting the DNA duplex with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-[[(4-methoxyphenyl)acetyl]amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 136, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-H-pyrrol-3-yl]-4-[(3,3-dimethylbutanoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 137, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 138, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[3-(-(Dimethylamino)propyl]2-2({[4-({[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 139, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-({[4-(formylamino)-1-isopropyl-1H-pyrrol-2-yl]carbonyl}-amino)-1-isopropyl-1H-pyrrole-2-carboxamide.

Group 140, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopentyl-1H-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(formyl-amino)-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 141, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-(formyl-amino)-1-isopropyl-1H-pyrrole-2-carboxamide.

Group 142, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]2-({[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 143, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound 4-({[4-(Formylamino)-1-methyl-1-H-pyrrol-2-yl]carbonyl}amino)1-isopropyl-N-[1-methyl-5-({3-(4-morpholinyl)propyl]amino}carbonyl)-1H-pyrrol-3-yl]-1H-pyrrole-2-carboxamide.

Group 144, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound 4-(Formylamino)-N-[1-isopropyl-5-([[1-methyl-5-([[3-(1-pyrrolidinyl)-propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl- 1H-pyrrole-2-carboxamide.

Group 145, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1- H-pyrrole-2-carboxamide.

Group 146, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound 2-(Acetylamino)-N-[5-([[5-([[3-(dimethylamino)propyl]amino]-carbonyl)-1-m- ethyl-1H-pyrrol-3-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 147, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound 2-(Acetylamino)-N-[5-([[4-([[3-(dimethylamino)propyl]amino]-carbonyl)-5-i- sopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 148, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound 2-(Acetylamino)-N-(5-[[(3-[[3-(dimethylamino)propyl]amino]-3-oxo-propyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)-5-isopropyl-1,3-thiazole-4-carboxamide.

Group 149, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting

each DNA duplex with a compound N^1,N^3-Bis(2-[[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)- -5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-amino]-2-oxoethyl)isophthalamide.

Group 150, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopropyl-1H-pyrrol-3-yl]-4-(acetylamino)-1-methyl-1-H-pyrrole-2-carboxamide.

Group 151, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-(acetyl-amino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 152, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N^2,N^5-Bis[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 153, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N^2,N^5-Bis[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]-amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 154, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N^2,N^5-Bis[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)-propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 155, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N^2,N^5-Bis[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)-propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1H-indole-2,5-dicarboxamide.

Group 156, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound 2-([[4-([[4-(Acetylamino)-1-methyl-1H-imidazol-2-

yl]carbonyl]-amino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino)-N-[3-(dimethylamino)-propyl]-5-isoprop-yl-1,3-thiazole-4-carboxamide.

Group 157, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound 4-(Acetylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl) propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide.

Group 158, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[1-Isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)-propyl]amino-]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 159, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-([[5-(formylamino)-2-methyl-3-thienyl]carbonyl]amino)-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 160, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-([[5-([[3-(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-5-isopropyl-2-[(3-methoxybenzoyl)amino]-1,3-thiazole-4-carboxamide.

Group 161, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-4-[[(5-[[(9,10-dioxo-9,10-dihydro-2-anthracenyl)carbonyl]-amino]-2-methyl-- 3-thienyl)carbonyl]amino]-1-isopentyl-1H-pyrrole-2-carboxamide.

Group 162, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[1-(Cyclopropylmethyl)-5-([[5-([[3-(dimethylamino)propyl]-amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-4-(formylamino)-1-methyl-1H-pyrrole-2-carboxamide.

Group 163, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound 1-Cyclopentyl-N-[5-([[3-

(dimethylamino)propyl]amino]carbonyl)-1-methyl-1H- -pyrrol-3-yl]-4-([[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]-carbonyl]-amino)-1H-pyrrole-2-carboxamide.

Group 164, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N^2,N^7-Bis[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide.

Group 165, claim(s) claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound 4-(Formylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide.

Group 166, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound 4-(Acetylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1-H-pyrrole-2-carboxamide.

Group 167, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound 4-(Formylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-morpholinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1-H-pyrrole-2-carboxamide.

Group 168, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

Group 169, claim(s) 92, drawn to a method of enhancing the difference in melting temperatures between first and second DNA duplex, method comprising contacting each DNA duplex with a compound N-[5-([[5-([[3-(Dimethylamino)propyl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]amino]carbonyl)-1-isopentyl-1H-pyrrol-3-yl]-4-[[(4-methoxyphenyl)acetyl]amino]-1-methyl-1H-pyrrole-2-carboxamide.

Linking Claims

2. Claims 50-74, 78-82 and 94 link(s) inventions 1 through 34. The restriction requirement among the linked inventions is **subject to** the nonallowance of the linking claim(s), claims 50-74, 78-85 and 94. Upon the indication of allowability of the linking claim(s), the restriction requirement as to the linked inventions **shall** be withdrawn and any claim(s) depending from or otherwise requiring all the limitations of the allowable linking claim(s) will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104 **Claims that require all the limitations of an allowable linking claim** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

3. Applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, the allowable linking claim, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

4. A national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:

(1) a product and a process specially adapted for the manufacture of said product; or

(2) a product and a process of use of said product; or

(3) a product, a process specially adapted for the manufacture of the said product, and a use of the said product; or

(4) a process and a apparatus specifically designed for carrying out said process; or

(5) a product, a process specially adapted for the manufacture of the said product and an apparatus specifically designed for carrying out said process. 37 CFR 1.475.

Group I, having a first product and a first method for using the said product fall within category (2). PCT Rule 13 does not provide for multiple compositions or multiple methods of use within a single application. Thus, the first appearing composition is combined with a corresponding first method of making and the additional composition and method claims each constitute a separate group.

5. The inventions listed as Groups 1-169 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The compounds are distinct because the structures are different. For example, 4-(Formylamino)-N-[1-isopentyl-5-([[1-methyl-5-([[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl)-1H-pyrrol-3-yl]amino]carbonyl)-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide is different from N^2,N^7-Bis[5-([[4-([[3-(dimethylamino)propyl]amino]carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino]carbonyl)-1-methyl-1H-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide. Further, search for one would not lead to the other. Independent searches are required to search for the different compounds. Further, there is no common structure present.

The situation involving the so-called Markush practice wherein a single claim defines alternatives (chemical or non-chemical) is also governed by PCT Rule 13.2. In this special situation, the requirement of a technical interrelationship and the same or corresponding special technical features as defined in PCT Rule 13.2, shall be considered to be met when the alternatives are of a similar nature.

When the Markush grouping is for alternatives of chemical compounds, they shall be regarded as being of a similar nature where the following criteria are fulfilled:

(A) All alternatives have a common property or activity; and

(B)

(1) A common structure is present, i.e., a significant structural element is shared by all of the alternatives; or

(B)

(2) In cases where the common structure cannot be the unifying criteria, all alternatives belong to a recognized class of chemical compounds in the art to which the invention pertains.

In paragraph (B)(1), above, the words "significant structural element is shared by all of the alternatives" refer to cases where the compounds share a common chemical structure which occupies a large portion of their structures, or in case the compounds have in common only a small portion of their structures, the commonly shared structure

constitutes a structurally distinctive portion in view of existing prior art, and the common structure is essential to the common property or activity. The structural element may be a single component or a combination of individual components linked together.

In paragraph (B)(2), above, the words "recognized class of chemical compounds" mean that there is an expectation from the knowledge in the art that members of the class will behave in the same way in the context of the claimed invention. In other words, each member could be substituted one for the other, with the expectation that the same intended result would be achieved.

6. Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

(a) the inventions have acquired a separate status in the art in view of their different classification;

(b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;

(c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);

(d) the prior art applicable to one invention would not likely be applicable to another invention;

(e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

7. **Applicant is advised that the reply to this requirement to be complete must include (i) an election of a invention to be examined** even though the requirement

may be traversed (37 CFR 1.143) **and (ii) identification of the claims encompassing the elected invention**.

8. The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

9. If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

10. **Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.**

Conclusion

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Julie Ha whose telephone number is 571-272-5982. The examiner can normally be reached on Mon-Fri, 8:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Julie Ha
Patent Examiner
AU 1654

ANISH GUPTA
PRIMARY EXAMINER